Devonian Health Group Inc. announced plans to list its common shares and warrants on the NYSE American, with trading expected to start as early as September 16, 2026. The company will continue its listing on the TSX Venture Exchange and intends to change its TSXV trading symbol from "GSD" to "DHGR". Devonian specializes in developing drugs for autoimmune fibroinflammatory diseases and aims to expand its market presence through this dual listing. This move could increase visibility and liquidity for investors in the company’s shares.
Argus Research increased its price target for NetApp to $225, citing a 13.5% potential upside from the current price of $198.18. NetApp reported strong fiscal Q1 2027 results with revenues up 29.9% to over $2 billion and non-GAAP EPS rising 66.5% to ...
New Jersey American Water received approval for rate increases that will add $68 million annually to its revenue. This funding supports over $1.4 billion in critical infrastructure upgrades, including replacing aging water mains and improving treatme...
MoneyHero Limited reported Q3 2026 earnings with an EPS of -$0.03 and revenue of $15.75 million, missing analyst estimates. The company is shifting strategy to offer more cash rewards to attract users, which has lowered immediate revenue and resulted...
Journey Energy has acquired a private company owning a 0.98% interest in the Keyera Rimbey gas processing facility for $8 million. This asset generates about $0.7 million annually in third-party processing revenue and is expected to reduce Journey's ...
Brodsky & Smith law firm is investigating ACV Auctions' Board of Directors for potential breaches of fiduciary duty related to the company's $1.9 billion sale to Copart, Inc. The probe questions whether the board conducted a fair process and if the $...
